All Stories

  1. Gene Variant in the NF-κB Pathway Inhibitor NFKBIA Distinguishes Patients with Psoriatic Arthritis within the Spectrum of Psoriatic Disease
  2. Very Low Disease Activity, DAPSA Remission, and Impact of Disease in a Spanish Population with Psoriatic Arthritis
  3. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis
  4. Registro Español de Artritis Psoriásica de Reciente Comienzo (estudio REAPSER). Objetivos y metodología
  5. Polyarticular evolution and late-onset psoriasis may be associated with cardiovascular disease in psoriatic arthritis
  6. Biological Dose Tapering in Daily Clinical Practice: A 10 Year Follow-up Study
  7. Minimal Disease Activity and Patient-Acceptable Symptom State in Psoriatic Arthritis
  8. Recomendaciones de la Sociedad Española de Reumatología sobre el tratamiento y uso de terapias sistémicas biológicas y no biológicas en artritis psoriásica
  9. Ustekinumab in psoriatic arthritis: need for studies from real-world evidence
  10. Norma de calidad para el manejo del paciente con artritis psoriásica: proyecto QUANTUM
  11. Recommendations for the Use of Methotrexate in Psoriatic Arthritis
  12. Remission and stringent treatment goals in psoriatic arthritis: Doctors’ opinion is not enough
  13. Recomendaciones sobre el uso de metotrexato en pacientes con artritis psoriásica
  14. Anti-MDA5 dermatomyositis mimicking psoriatic arthritis
  15. Patient-reported outcomes in European spondyloarthritis patients: a systematic review of the literature
  16. Prevalence and type II diabetes-associated factors in psoriatic arthritis
  17. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain
  18. Estado actual de la atención multidisciplinar para pacientes con artritis psoriásica en España: proyecto NEXUS 2.0
  19. Enfermedad de Pyle: un modelo humano de homeostasis corticotrabecular diferenciada
  20. Impact of cardiovascular risk factors on the achievement of therapeutic goals in psoriatic arthritis: is there any association?
  21. Performance of Two Screening Questionnaires for Inflammatory Arthritis in Patients with Inflammatory Bowel Disease
  22. Recommendations for the management of comorbidity in hidradenitis suppurativa
  23. L’âge à l’apparition du rhumatisme psoriasique pourrait faciliter la caractérisation de son phénotype
  24. NFKBIZ in Psoriasis: Assessing the association with gene polymorphisms and report of a new transcript variant
  25. Minimal disease activity and impact of disease in psoriatic arthritis: a Spanish cross-sectional multicenter study
  26. Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España
  27. Multidisciplinary care for psoriatic disease
  28. Age at disease onset may help to further characterize the disease phenotype in psoriatic arthritis
  29. Urine metabolome profiling of immune-mediated inflammatory diseases
  30. A Single Nucleotide Polymorphism in the Il17ra Promoter Is Associated with Functional Severity of Ankylosing Spondylitis
  31. Association of IL1Β (-511 A/C) and IL6 (-174 G > C) polymorphisms with higher disease activity and clinical pattern of psoriatic arthritis
  32. Common and rareCARD14gene variants affect the antitumour necrosis factor response among patients with psoriasis
  33. CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients
  34. Association between single nucleotide polymorphisms IL17RA rs4819554 and IL17E rs79877597 and Psoriasis in a Spanish cohort.
  35. HLA-B27 and psoriatic disease: a modern view of an old relationship
  36. Cardiovascular risk factors influence response to biological therapies in psoriasis
  37. AB0823 Age at Disease Onset Helps to Further Characterize the Disease Phenotype in Psoriatic Arthritis
  38. AB0824 Predictors of Cerebrovascular Disease Among Psoriatic Arthritis Patients
  39. AB1133 Epidemiological Comparative Analysis in a Large Cohort of Psoriatic Arthritis Patients: Results of the Spanish IMID Consortium
  40. A deletion atADAMTS9-MAGI1locus is associated with psoriatic arthritis risk
  41. Activating killer immunoglobulin-like receptors genes are associated with increased susceptibility to ankylosing spondylitis
  42. Reccomendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care
  43. Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención Primaria
  44. The Cw6 and late-cornified envelope genotype plays a significant role in anti-tumor necrosis factor response among psoriatic patients
  45. The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients
  46. Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis
  47. Ankylosing Spondylitis without Axial Progression: Analysis of Associated Factors
  48. Comprehensive Treatment of Dactylitis in Psoriatic Arthritis
  49. PDE3A-SLCO1C1locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis
  50. Genetic variation at IL12B, IL23R and IL23A is associated with psoriasis severity, psoriatic arthritis and type 2 diabetes mellitus
  51. Effect of the FTO rs9930506 polymorphism on obesity and the main clinical outcomes in patients with psoriasis
  52. AB0736 Strategy for the Early Detection and Referral of Patients with Suspected Spondyloarthritis: Table 1
  53. AB0764 An Onset of Psoriasis after 40 Years and A Low Education Level May PREDICT the Development of Diabetes Mellitus in Psoriatic Arthritis
  54. SAT0410 Determinants of Hypertension in Patients with Psoriatic Arthritis
  55. Recommendations for the Coordinated Management of Psoriatic Arthritis by Rheumatologists and Dermatologists: A Delphi Study
  56. Standards of care for patients with spondyloarthritis
  57. The Region Centromeric to HLA-C Is a Key Region for Understanding the Phenotypic Variability of Psoriatic Arthritis
  58. Age at disease onset: a key factor for understanding psoriatic disease
  59. Psoriasis, psoriatic arthritis and type 2 diabetes mellitus: a systematic review and meta-analysis
  60. SNP rs11652075 in the CARD14 Gene as a Risk Factor for Psoriasis (PSORS2) in a Spanish Cohort
  61. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
  62. Diferente expresión clínica de los pacientes con espondilitis anquilosante según el sexo en función del tiempo de evolución. Datos de REGISPONSER
  63. Different Clinical Expression of Patients With Ankylosing Spondylitis According to Gender in Relation to Time Since Onset of Disease. Data From REGISPONSER
  64. AB0588 Prevalence of conventional cardiovascular risk factors in patients with psoriasis alone and in patients with psoriatic arthritis
  65. FRI0556 Development of standards of care in spondyloarthritis
  66. SAT0311 Men and women with psoriatic arthritis express a different genetic profile within the major histocompatibility complex region
  67. Erosive discovertebral lesion (Andersson lesion) as the first sign of disease in axial psoriatic arthritis
  68. Long-term tolerability and maintenance of therapeutic response to sodium oxybate in an open-label extension study in patients with fibromyalgia
  69. Dropped Head Syndrome in a Patient With Scleromyositis
  70. Clinical Differences between Men and Women with Psoriatic Arthritis: Relevance of the Analysis of Genes and Polymorphisms in the Major Histocompatibility Complex Region and of the Age at Onset of Psoriasis
  71. Resequencing of the IL12B gene in psoriasis patients with the rs6887695/rs3212227 risk genotypes
  72. Ustekinumab en la artritis psoriásica y la enfermedad de Crohn
  73. Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes
  74. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
  75. Uso del cuestionario Hospital Anxiety and Depression Scale (HADS) para evaluar la ansiedad y la depresión en pacientes con fibromialgia
  76. Actualización en la patogenia de la artritis psoriásica
  77. Entheseal ultrasound abnormalities in patients with SAPHO syndrome
  78. A high density SNP genotyping approach within the 19q13 chromosome region identifies an association of a CNOT3 polymorphism with ankylosing spondylitis
  79. Psoriasis and psoriasiform lesions induced by TNFα antagonists: the experience of a tertiary care hospital from northern Spain
  80. Implantation d’un filtre cave inférieur dans le corps de la troisième vertèbre lombaire
  81. HLA-DR17 est associé à une enthésite dans le rhumatisme psoriasique
  82. La stratification par âge d’apparition de la maladie avec limite fixée à 30ans : une méthode efficace pour identifier le psoriasis associé à PSORS1 chez les patients atteints de rhumatisme psoriasique
  83. Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis
  84. Consenso SER sobre la gestión de riesgo del tratamiento con terapias biológicas en pacientes con enfermedades reumáticas
  85. Consensus Statement of the Spanish Society of Rheumatology on Risk Management of Biologic Therapy in Rheumatic Patients
  86. HLA-DR17 is associated with enthesitis in psoriatic arthritis
  87. High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study)
  88. Documento SER de consenso sobre el uso de terapias biológicas en la artritis psoriásica
  89. Consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in psoriatic arthritis
  90. Power Doppler Ultrasonography Assessment of Entheses in Spondyloarthropathies: Response to Therapy of Entheseal Abnormalities
  91. Comorbilidades en las espondiloartropatías
  92. Factors associated with temporary work disability in patients with fibromyalgia
  93. Mutation analysis of the LCE3B/LCE3C genes in Psoriasis
  94. Terapias biológicas distintas de la terapia anti-TNFα en la psoriasis y la artritis psoriásica
  95. Determinants of psoriatic arthritis in patients with psoriasis
  96. Development of a self-reporting tool to obtain a Combined Index of Severity of Fibromyalgia (ICAF*)
  97. Hip involvement in ankylosing spondylitis: epidemiology and risk factors associated with hip replacement surgery
  98. Clinical expression, but not disease outcome, may vary according to age at disease onset in psoriatic spondylitis
  99. L’expression clinique, contrairement aux paramètres évolutifs, peut varier selon l’âge de début de la maladie dans le rhumatisme psoriasique
  100. ¿Es útil el ejercicio en el tratamiento de la espondilitis anquilosante?
  101. May Some Cases of Intermittent Hydrarthrosis Represent an Atypical Form of Calcium Pyrophosphate Dihydrate Crystal Deposition Disease? Usefulness of Mutational Analysis of the MEFV Gene
  102. MHC class I chain-related gene B (MICB) is associated with rheumatoid arthritis susceptibility
  103. An unexpectedly high frequency ofMEFV mutations in patients with anti–citrullinated protein antibody–negative palindromic rheumatism
  104. Desarrollo y validación de un cuestionario de satisfacción con el tratamiento en pacientes con artritis reumatoide
  105. Tratamientos en artritis reumatoide precoz
  106. Association of intermittent hydrarthrosis withMEFV gene mutations
  107. Tratamientos no biológicos en la artritis psoriásica
  108. The effect of HLA‐DR antigens on the susceptibility to, and clinical expression of psoriatic arthritis
  109. RS3PE syndrome: a clinical and immunogenetical study
  110. Successful therapy with low-dose colchicine in intermittent hydrarthrosis
  111. A polyarticular onset predicts erosive and deforming disease in psoriatic arthritis
  112. Spectrum of psoriatic spondyloarthropathy in a cohort of 100 Spanish patients
  113. Successful Treatment with Low-Dose Weekly Methotrexate in a Case of Undifferentiated Spondyloarthropathy coexisting with Cutaneous Polyarteritis Nodosa
  114. C4 deficiency state in antiphospholipid antibody-related recurrent preeclampsia evolving into systemic lupus erythematosus
  115. Psoriatic spondyloarthropathy: A comparative study between HLA-B27 positive and HLA-B27 negative disease
  116. Clinical features and predictive factors in psoriatic arthritis–related uveitis
  117. Clinically Asymptomatic Axial Disease in Psoriatic Spondyloarthropathy. A Retrospective Study
  118. Prevalence and Predictors of Cervical Involvement in Psoriatic Spondyloarthropathy
  119. Comparative analysis of psoriatic spondyloarthropathy between men and women
  120. Manifestaciones atípicas de la enfermedad de Whipple
  121. Subclinical Sacroiliitis in Inflammatory Bowel Disease: A Clinical and Follow-up Study
  122. Haematogenous Vertebral Osteomyelitis in the Elderly
  123. Multiple painful bone cysts in a young man.
  124. Psoriatic Arthropathy after BCG Immunotherapy for Bladder Carcinoma